Most patients with hepatitis C virus infection develop chronicity and can progress to cirrhosis. Prognosis for treatment of hepatitis C virus infection: A combination of treatments should be given. Treatment for cirrhosis is the same as for other causes of cirrhosis. Antiviral therapy given to patients with hepatitis C cirrhosis may stop or delay the progression of cirrhosis if a sustained virological response is obtained. Antiviral therapy: Patients with compensated cirrhosis (Child-Pugh class A) are recommended to be given antiviral therapy under the guidance of an experienced physician under close observation in order to stabilize the disease and delay or stop the development of complications such as liver failure and HCC, despite the reduced tolerance and effectiveness of the treatment. The regimen is as follows: 1) pegylated interferon combined with ribavirin regimen, test HCV RNA up to 12 weeks, and consider discontinuing the drug if HCV RNA decreases < 2 log levels; if HCV RNA is negative in qualitative testing or below the minimum detection limit of the quantitative method, continue treatment until 48 weeks; if HCV RNA does not turn negative but decreases ≥ 2 log levels, continue treatment until 24 If HCV RNA is negative at 24 weeks, continue treatment until 48 weeks; if it is not negative at 24 weeks, discontinue treatment for observation. 2) Common interferon combined with ribavirin regimen: 48 weeks of treatment is recommended. Patients with hepatic decompensation and cirrhosis are mostly difficult to tolerate the adverse effects of interferon therapy, and liver transplantation should be performed if available.